Loading viewer...
earnings
Format: PDF earnings
Q1 2017 supplemental earnings presentation dated March 7, 2017. Reports sales of $391.7M (+5.9% YoY) with gross margins of 21.4% impacted by product mix shifts and rising steel costs. Net income decreased to $2.0M ($0.03 per diluted share) versus prior year.
investor_presentation
18 Pages
earnings
20 Pages
Rigel Pharmaceuticals